Baxter International Inc. · NYSE:BAX
Baxter International — 40th Annual J.P. Morgan Healthcare Conference (January 2022)
17 slides from Baxter International's conference presentation, Jan 10, 2022
Slide 1: 40th Annual J.P. Morgan Healthcare Conference
40th Annual J.P. Morgan Healthcare Conference José (Joe) E. Almeida, Chairman & Chief Executive Officer January 10, 2022
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation includes forward-looking statements concerning projected financial results (including anticipated cost synergies, margin expansion and estimated ROIC and adjusted EPS improvement resulting from the Hillrom acquisition), business development activities, capital
Slide 3: Uniquely Positioned To Deliver Value To Stakeholders
Uniquely Positioned To Deliver Value To Stakeholders Baxter Key Competencies Medically necessary Global manufacturing Inclusive & innovative products and therapies expertise workplace For 90 Years, Baxter Has Operated At The Critical Intersection Of Saving And Sustaining Lives 3
Slide 4: The Baxter Journey
The Baxter Journey 2016–2017: 2018–2020: 2021 and Beyond: A Fresh Start Building the Foundation Accelerating Transformation ✓ Realigned structure to drive innovation ✓ Refined corporate strategy Integrating ✓ Created regional go-to-market strategies ✓ Bolstered organic innovation and R&D productivit
Slide 5: Strategic Combination Focused On Transforming Healthcare And Creating Value
Strategic Combination Focused On Transforming Healthcare And Creating Value ▪ Participating in additional $40B+ TAM with Evaluating a 5%+ WAMGR1 ▪ Developing strategic framework to deliver Revenue Growth enhanced value to patients and providers Opportunities ▪ Assessing opportunities to accelerate s
Slide 6: Baxter Now: Our Global Scale
Baxter Now: Our Global Scale1 FY 2020 Combined FY 2020 Combined Global Revenue Revenue by Geography U.S. 47% $14.6B OUS 53% 1Pro forma amounts as presented on this slide represent the combined results of Baxter for its fiscal year ended 12/31/2020 and Hillrom for its fiscal year ended 6 09/30/2020.
Slide 7: Baxter Now: Our Product Categories
Baxter Now: Our Product Categories1 Renal Care Medication Delivery Pharmaceuticals Patient Support Systems Front Line Care $3.8B $2.7B $2.1B $1.5B $1.0B Clinical Nutrition Advanced Surgery Acute Therapies BioPharma Solutions Global Surgical Solutions $0.9B $0.9B $0.7B $0.5B $0.3B Legacy Baxter Legac
Slide 8: Connected Care Framework
Connected Care Framework Advancing our Mission to Save and Sustain Lives Vision to transform healthcare by improving patient outcomes, enhancing workflow efficiency and enabling more cost-effective healthcare solutions Smart Devices Data & Analytics Communications Significant installed base of conne
Slide 9: Connected Care Example
Connected Care Example Mission: Save and Sustain Lives Vision: Improve the safety of IV therapy while reducing alarm fatigue and giving front line teams more time for enhanced patient care Smart Devices Data & Analytics Communications Infusion pumps integrated with EMR Machine learning tool to enhan
Slide 10: Potential Near-term Commercial Synergy Opportunities
Potential Near-term Commercial Synergy Opportunities Hospital Alternate Sites of Care Home Portfolio Geographic Sites of Care Enhanced Technical Expansion Expansion Services Offering 10
Slide 11: Innovation Ecosystem
Innovation Ecosystem New Product Launches Meeting The Needs Of Patients And Providers Novum IQ Suite1 Premix Injectables PanOptic & Prismax 2 Strengthening Ready-to-use MacroView Plus1 Single platform with competitive portfolio expansion New digital-ready ability to deliver positioning with with lau
Slide 12: Line Of Sight To Value Creation Through Cost Synergies
Line Of Sight To Value Creation Through Cost Synergies Expect to realize ~$250M of cost synergies by year 3, with additional opportunities thereafter Key Value Capture Initiatives ~$250M Operating Model • Optimizing organizational design • Simplifying and digitizing processes Procurement • Contracti
Slide 13: Executing Disciplined Capital Allocation Strategy
Executing Disciplined Capital Allocation Strategy REINVEST IN SHARE BUSINESS DIVIDENDS REPURCHASE M&A Meeting the needs of Announced quarterly Expect to moderate Unwavering commitment patients and providers dividend of $0.28 per repurchases in the near- to successfully globally while continuing shar
Slide 14: 2030 Corporate Responsibility Commitment And Goals
2030 Corporate Responsibility Commitment And Goals ► Achieve carbon neutrality for ► Bring home dialysis to ► Invest $275 million in direct operations by 2040 more underserved underserved communities ► Reduce greenhouse gas patients ► Achieve top workplace emissions ► Improve product safety performa
Slide 15: Driving Compelling Value For All Stakeholders
Driving Compelling Value For All Stakeholders Our Patients and Combining complementary portfolios with connected Providers care offerings to improve patient outcomes, enhance workflow efficiency and enable more cost-effective healthcare solutions Our People Uniting talented, diverse employees who ha
Slide 16: Continuing Momentum In 2022 And Beyond
Continuing Momentum In 2022 And Beyond • Focused on successfully integrating Hillrom business • Executing on value capture initiatives and assessing potential revenue growth opportunities • Committed to delivering enhanced operating margin and improved cash flow generation • Plan to host an Investor
Slide 17: Save + Sustain Lives
Advancing Our Mission Save + Sustain Lives 17
Baxter International — 40th Annual J.P. Morgan Healthcare Conference (January 2022) on 6ix